Nitisinone

Nitisinone is an orally active, competitive and reversible 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor with an IC50 of 173 nM. Nitisinone promotes tyrosine accumulation in a dose-dependent manner. nitisinone can be used in studies of hereditary tyrosinemia type 1 (HT-1) (a rare genetic disorder) and albinism[1][2][3][4].

Product Specifications

CAS Number

[104206-65-7]

Product Name Alternative

NTBC; Nitisone; SC0735

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HPPD

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Nitisinone.html

Purity

99.93

Solubility

DMSO : 41.67 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C(C(C2=CC=C(C(F)(F)F)C=C2[N+]([O-])=O)=O)C(CCC1)=O

Molecular Formula

C14H10F3NO5

Molecular Weight

329.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Laschi M, et al. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria. ChemMedChem. 2016 Apr 5;11 (7) :674-8.|[2]Ellis MK, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2- (2-nitro-4-trifluoromethylbenzoyl) -cyclohexane-1,3-dione and 2- (2-chloro-4-methanesulfonylbenzoyl) -cyclohexane-1,3-dione. Toxicol Appl Pharmacol. 1995 Jul;133 (1) :12-9. |[3]Onojafe IF, et al. Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. J Clin Invest. 2011 Oct;121 (10) :3914-23. |[4]Aktuglu-Zeybek A, et al. Nitisinone: a review. Orphan Drugs: Research and Reviews, 2017, 7.